Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Remuiñán, Modesto J ^a   Pérez Herrán, Esther ^a   Rullás, Joaquín ^a   Alemparte, Carlos ^a   Martínez Hoyos, María ^a   Dow, David J ^b   Afari, Johnson ^b   Mehta, Nalini ^b   Esquivias, Jorge ^a   Jiménez, Elena ^a   Ortega Muro, Fátima ^a   Fraile Gabaldón, María Teresa ^a   Spivey, Vickey L ^b   Loman, Nicholas J ^c   Pallen, Mark J ^c   Constantinidou, Chrystala ^c   Minick, Douglas J ^d   Cacho, Mónica ^a   Rebollo López, María José ^a   González, Carolina ^a   Sousa, Verónica ^a   Angulo Barturen, Iñigo ^a   Mendoza Losana, Alfonso ^a   Barros, David ^a   Besra, Gurdyal S ^c   Ballell, Lluís ^a   Cammack, Nicholas ^a   more..

^a GLAXOSMITHKLINE   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ETHAMBUTOL; LINEZOLID; MOXIFLOXACIN; MYCOBACTERIAL MEMBRANE PROTEIN LARGE FAMILY 3; N BENZYL 69,79 DIHYDROSPIRO[PIPERIDINE 4,4' THIENO [3,2 C]PYRAN] DERIVATIVE; TETRAHYDROPYRAZOLO [1,5 A]PYRIMIDINE 3 CARBOXAMIDE DERIVATIVE; TREHALOSE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHROMATOGRAPHY, THIN LAYER; CORD FACTORS; DISEASE MODELS, ANIMAL; DOGS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HEP G2 CELLS; HUMANS; KINETICS; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZOLES; RATS; SPIRO COMPOUNDS; TREATMENT OUTCOME; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 84876272210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060933     Document Type: Article

References (25)

1. WHO (2011) Global Tuberculosis Control: WHO report 2011. Geneva: World Health Organization.
2. Dye C, Williams BG, (2010) The population dynamics and control of tuberculosis. Science 328: 856-861.
3. Berry M, Kon O M, (2009) Multidrug- and extensively drug-resistant tuberculosis: an emerging threat. Eur. Respir. Rev. 18: 195-197.
4. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K, (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Drug Discovery 6: 29-40.
6. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, et al. (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. Nacy Journal of Antimicrobial Chemotherapy 56: 968-974.
7. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
8. Andries K, Verhasselt P, Guillemont J, Goehlmann HWH, Neefs JM, et al. (2005) Diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
9. Biava M, Porretta GC, Poce G, Supino S, Deidda D, et al. (2006) Novel diarylpirrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. J. Med. Chem. 49: 4946-4952.
10. Pethe K, Sequeira P, Agarwalla S, Rhee K, Kuhen K, et al. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1: 57.
11. Ballell LL, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, et al. (2013) Fueling Open Source Drug Discovery: New Small Molecule Leads Against Tuberculosis ChemMedChem. 8: 313.
12. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, et al. (2009) Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science 324: 801-804.
13. Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
14. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, et al. (2012) SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56: 1797-1809.
15. La Rosa V, Poce G, Ortiz Canseco J, Buroni S, Pasca MR, et al. (2012) MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56: 324-331.
16. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, et al. (2012) Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8: 334-341.
17. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, et al. (2012) Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7(8): 1377-84.
18. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis 89: 354-363.
19. Varela C, Rittmann D, Singh A, Krumbach K, Bhatt K, et al. (2012) MmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria. Chemistry & Biology 19: 498-506.
20. Rullas J, García JI, Beltrán M, Cardona P-J, Cáceres N, et al. (2010) Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob. Agents Chemother. 54: 2262 -2264.
21. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-44.
22. Hill A, Young RJ, (2010) Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug discovery today 15: 648-55.
23. Murray M, (2000) Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab. 1: 67-84.
24. Blagg J (2010) Structural Alerts for Toxicity. Burger's Medicinal Chemistry, Drug Discovery and Development. DOI: 10.1002/0471266949.bmc128.
25. Dobson G., Minnikin D.E., Minnikin S.M., Parlett J.H., Goodfellow M., et al. (1985) Systematic analysis of complex mycobacterial lipids. In: Chemical Methods in Bacterial Systematics. Goodfellow, M., and Minnikin, D.E. (eds). London: Academic Press. 237-265.